U.S. markets closed

Santen Pharmaceutical Co., Ltd. (SNPHY)

Other OTC - Other OTC Delayed Price. Currency in USD
8.39+0.23 (+2.86%)
At close: 11:54AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.16
Bid0.00 x 0
Ask0.00 x 0
Day's Range8.39 - 8.39
52 Week Range6.20 - 12.84
Avg. Volume27,965
Market Cap3.151B
Beta (5Y Monthly)0.43
PE Ratio (TTM)17.86
EPS (TTM)0.47
Earnings DateN/A
Forward Dividend & Yield0.26 (3.24%)
Ex-Dividend DateSep 29, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SNPHY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: MERCK Kommanditgesellschaft auf AktienMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
    Fair Value
    Economic Moat
    17 days agoMorningstar
View more
  • Zacks Small Cap Research

    RVLP: Can’t Take My Eyes Off You

    By John Vandermosten, CFA NASDAQ:RVLP READ THE FULL RVLP RESEARCH REPORT We are initiating coverage of RVL Pharmaceuticals, plc (NASDAQ:RVLP) with a valuation of $3.60 per share. RVL’s lead and only marketed asset is Upneeq®, a product developed to treat acquired blepharoptosis, or low-lying eyelids. Following approval for Upneeq in July 2020, RVL embarked on a structured commercialization effort